tiprankstipranks
Trending News
More News >
Third Harmonic Bio, Inc. (THRD)
:THRD
US Market
Advertisement

Third Harmonic Bio, Inc. (THRD) Price & Analysis

Compare
Followers

THRD Stock Chart & Stats


Third Harmonic Bio, Inc. News

THRD FAQ

What was Third Harmonic Bio, Inc.’s price range in the past 12 months?
Currently, no data Available
What is Third Harmonic Bio, Inc.’s market cap?
Currently, no data Available
When is Third Harmonic Bio, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Third Harmonic Bio, Inc.’s earnings last quarter?
Currently, no data Available
Is Third Harmonic Bio, Inc. overvalued?
According to Wall Street analysts Third Harmonic Bio, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
    Does Third Harmonic Bio, Inc. pay dividends?
    Third Harmonic Bio, Inc. does not currently pay dividends.
    What is Third Harmonic Bio, Inc.’s EPS estimate?
    Third Harmonic Bio, Inc.’s EPS estimate for its next earnings report is not yet available.
    How many shares outstanding does Third Harmonic Bio, Inc. have?
    Currently, no data Available
    What happened to Third Harmonic Bio, Inc.’s price movement after its last earnings report?
    Currently, no data Available
    Which hedge fund is a major shareholder of Third Harmonic Bio, Inc.?
    Currently, no hedge funds are holding shares in THRD

    Company Description

    Third Harmonic Bio, Inc.

    Third Harmonic Bio, Inc. (THRD) is a biopharmaceutical company focused on the discovery and development of innovative therapies for the treatment of allergic and inflammatory diseases. Leveraging its expertise in immunology and drug development, the company aims to address unmet medical needs by creating targeted therapies that modulate specific pathways involved in allergic and inflammatory responses.

    Third Harmonic Bio, Inc. (THRD) Earnings & Revenues

    Currently, no data available
    Please return soon. This page is being updated.
    Similar Stocks
    Company
    Price & Change
    Follow
    Cardiff Oncology
    Neurogene
    Annexon Biosciences
    Innate Pharma
    Design Therapeutics

    Ownership Overview

    4.15%92.14%
    Insiders
    ― Other Institutional Investors
    92.14% Public Companies and
    Individual Investors

    Options Prices

    Currently, No data available
    ---
    Popular Stocks
    What am I Missing?
    Make informed decisions based on Top Analysts' activity
    Know what industry insiders are buying
    Get actionable alerts from top Wall Street Analysts
    Find out before anyone else which stock is going to shoot up
    Get powerful stock screeners & detailed portfolio analysis